- Home
- ASRT vs HLVX Comparison
ASRT vs HLVX Comparison
Compare ASRT & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- HLVX
- Stock Information
- Founded
- ASRT 1995
- HLVX 2020
- Country
- ASRT United States
- HLVX United States
- Employees
- ASRT N/A
- HLVX 90
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- ASRT Health Care
- HLVX Health Care
- Exchange
- ASRT Nasdaq
- HLVX Nasdaq
- Market Cap
- ASRT 78.3M
- HLVX 86.2M
- IPO Year
- ASRT 1997
- HLVX 2022
- Fundamental
- Price
- ASRT $0.72
- HLVX $1.73
- Analyst Decision
- ASRT Strong Buy
- HLVX Hold
- Analyst Count
- ASRT 3
- HLVX 5
- Target Price
- ASRT $3.25
- HLVX $2.33
- AVG Volume (30 Days)
- ASRT 329.2K
- HLVX 139.8K
- Earning Date
- ASRT 03-12-2025
- HLVX 05-08-2025
- Dividend Yield
- ASRT N/A
- HLVX N/A
- EPS Growth
- ASRT N/A
- HLVX N/A
- EPS
- ASRT N/A
- HLVX N/A
- Revenue
- ASRT $124,961,000.00
- HLVX N/A
- Revenue This Year
- ASRT N/A
- HLVX N/A
- Revenue Next Year
- ASRT $1.84
- HLVX N/A
- P/E Ratio
- ASRT N/A
- HLVX N/A
- Revenue Growth
- ASRT N/A
- HLVX N/A
- 52 Week Low
- ASRT $0.68
- HLVX $1.55
- 52 Week High
- ASRT $1.80
- HLVX $18.24
- Technical
- Relative Strength Index (RSI)
- ASRT 34.96
- HLVX 37.55
- Support Level
- ASRT $0.74
- HLVX $1.78
- Resistance Level
- ASRT $0.83
- HLVX $1.91
- Average True Range (ATR)
- ASRT 0.04
- HLVX 0.06
- MACD
- ASRT -0.00
- HLVX -0.00
- Stochastic Oscillator
- ASRT 26.90
- HLVX 5.26
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.